CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab. Authors here show that the change in levels of the chemokine CXCL13 shortly fo...

Full description

Bibliographic Details
Main Authors: Sheila K. Pierson, Laura Katz, Reece Williams, Melanie Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B. Oromendia, Philip Beineke, Alexander Fosså, Frits van Rhee, David C. Fajgenbaum
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34873-7

Internet

https://doi.org/10.1038/s41467-022-34873-7

Similar Items